Literature DB >> 2577298

Combination therapy with calcium-entry blockers and beta-adrenoceptor antagonists in hypertension.

P Sever1.   

Abstract

The use of more than one drug to control blood pressure may be necessary in up to 50% of hypertensive patients seen in clinical practice. A rational basis for combination therapy includes 1) the use of drugs that act on different physiological systems involved in blood-pressure control and 2) using a second drug to counteract reflex responses, which may limit the effectiveness of the first, and, 3) as is less commonly practiced, the use of low doses of two drugs that act on the same or different physiological systems to avoid the side effects encountered with higher doses of single agents. The hemodynamic effects of calcium-entry blocking drugs and beta-adrenoceptor blockers are complementary and synergism might be anticipated, particularly with the dihydropyridines and beta-blockers, since the latter prevent the short-term reflex increase in sympathetic activity occurring as a consequence of vasodilation. Although there are many studies advocating the benefits of such combinations, caution is required with combinations of beta-blockers and verapamil or diltiazem because of potential cardiac depressant effects resulting from the more complex effects of these calcium-channel blockers on cardiac myo-cytes and conducting tissue. Such problems would be more likely to be encountered in patients with long-standing hypertension and in whom poor left ventricular function and coro-nary artery disease may be present.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2577298     DOI: 10.1007/bf00148478

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  17 in total

1.  Primary prevention with metoprolol in patients with hypertension. Mortality results from the MAPHY study.

Authors:  J Wikstrand; I Warnold; G Olsson; J Tuomilehto; D Elmfeldt; G Berglund
Journal:  JAMA       Date:  1988-04-01       Impact factor: 56.272

2.  The voltage- and time-dependent effects of (-)-verapamil on the slow inward current in isolated cat ventricular myocardium.

Authors:  T Ehara; R Daufmann
Journal:  J Pharmacol Exp Ther       Date:  1978-10       Impact factor: 4.030

3.  Cardiovascular risk and risk factors in a randomized trial of treatment based on the beta-blocker oxprenolol: the International Prospective Primary Prevention Study in Hypertension (IPPPSH). The IPPPSH Collaborative Group.

Authors: 
Journal:  J Hypertens       Date:  1985-08       Impact factor: 4.844

4.  MRC trial of treatment of mild hypertension: principal results. Medical Research Council Working Party.

Authors: 
Journal:  Br Med J (Clin Res Ed)       Date:  1985-07-13

Review 5.  Differences in cardiovascular profile among calcium antagonists.

Authors:  N Taira
Journal:  Am J Cardiol       Date:  1987-01-30       Impact factor: 2.778

Review 6.  Review of the cardiovascular adversity of the calcium antagonist beta-blocker combination: implications for antihypertensive therapy.

Authors:  R M Brouwer; F Follath; F R Bühler
Journal:  J Cardiovasc Pharmacol       Date:  1985       Impact factor: 3.105

7.  Combination of verapamil and beta blockers in systemic hypertension.

Authors:  H Dargie; J Cleland; I Findlay; G Murray; G McInnes
Journal:  Am J Cardiol       Date:  1986-02-26       Impact factor: 2.778

8.  Beta-blockers versus diuretics in hypertensive men: main results from the HAPPHY trial.

Authors:  L Wilhelmsen; G Berglund; D Elmfeldt; T Fitzsimons; H Holzgreve; J Hosie; P E Hörnkvist; K Pennert; J Tuomilehto; H Wedel
Journal:  J Hypertens       Date:  1987-10       Impact factor: 4.844

9.  Effects of BAY l 5240, a fixed combination of low dose nifedipine and acebutolol on hypertension: comparison with standard dose nifedipine.

Authors:  P Lejeune; W Gunselmann; L Hennies; K Hess; K Rittgerodt; K Winn; G Gfrerer; U Schreiber
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

10.  Differentiation of calcium entry blockers into calcium channel blockers and calcium overload blockers.

Authors:  P A van Zwieten
Journal:  Eur Neurol       Date:  1986       Impact factor: 1.710

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.